New hope for taming a dangerous immune overreaction
NCT ID NCT06160791
Summary
This study is testing if adding the drug ruxolitinib to a slightly reduced version of the standard treatment regimen can effectively control a severe immune system disorder called HLH in adults. The goal is to see if this combination works as well as standard care but with fewer side effects. The study will enroll 36 newly diagnosed adult patients to evaluate how well they respond and how safe the treatment is.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, Irvine
RECRUITINGIrvine, California, 92697, United States
Contact
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.